<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004847</url>
  </required_header>
  <id_info>
    <org_study_id>PsoriasisCT02</org_study_id>
    <nct_id>NCT02004847</nct_id>
  </id_info>
  <brief_title>Blue Light for Treating Psoriasis Vulgaris</brief_title>
  <official_title>Monocenter, Randomized, Double Blinded, Intraindividual, Exploratory Study of Effectiveness and Safety of 3 Months Treatment With 2 Peak Intensities of 453nm Blue Light for the Treatment of Mild Plaque Type Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Light and Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philips Light and Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of a blue light device for
      treating Psoriasis vulgaris. The study will compare a blue light treated plaque with an
      untreated control plaque. Additionally, two intensities of blue light are compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blue light has been shown to release bioactive nitric oxide (NO) from nitrite and nitrosated
      proteins found in high concentrations in the skin. This bioactive NO has many physiological
      functions regulating immune responses, proliferation / differentiation as well as local blood
      Perfusion of the skin. The study will test the PSO-CT02 device, an new investigational
      medical device emitting blue light with a peak wavelength of 453nm on treating localised mild
      Psoriasis vulgaris. It can be worn on the Skin above the effected skin area. In this study
      Treatment (target) and control area as well as intensity of blue light are randomized. The
      control area will serve as reference. 50 Patients will treat the target area daily (at least
      5 times/week) at home for an initial treatment period of 4 weeks. During those 4 weeks,
      patients will return to the study site for safety and effectiveness assessments twice. After
      this initiation period patients will treat their plaque for further 8 weeks (3 times/week).
      This is followed by a 4 week follow up phase without treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline (Visit 2) of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity (HI) Group) as Compared to the Control Area at End of Treatment (Visit 7, Week 12).</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>In this study only the &quot;local&quot; PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity) as Compared to the Control Area at End of Treatment During the Attack Period (Week 4, Visit 5)</measure>
    <time_frame>baseline and week 4</time_frame>
    <description>In this study only the &quot;local&quot; PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 12 of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity) as Compared to the Control Area at End of Follow-up</measure>
    <time_frame>Week 12 and week 16</time_frame>
    <description>In this study only the &quot;local&quot; PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (Visit 2) of the Local Psoriasis Area Severity Index (PASI) of the Target Area (Low Intensity (LI) Group) as Compared to the Control Area by Week.</measure>
    <time_frame>baseline and week 4, 12, 16</time_frame>
    <description>In this study only the &quot;local&quot; PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Change From Baseline of Local Psoriasis Area Severity Index (PASI) Between Target and Control Area of the High Intensity (HI) Group as Compared to the Low Intensity (LI) Group</measure>
    <time_frame>baseline and week 4, 8, 16</time_frame>
    <description>In this study only the &quot;local&quot; PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0. = no sign
= slight
= moderate
= marked
= very marked A total severity score was calculated as the sum of the three symptom ratings (range 0-12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Erythema Evaluated by Mexameter of the Target Area of High Intensity (HI) and Low Intensity (LI) as Compared to the Control Area</measure>
    <time_frame>baseline and week 4, 12</time_frame>
    <description>Erythema was measured directly after treatment. Mexameter readings ranged from 0 to 100. Higher values describe higher erythema levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 12 (End of Treatment) of Erythema Evaluated by Mexameter of the Target Area of High Intensity (HI) and Low Intensity (LI) as Compared to the Control Area at End of Follow-up</measure>
    <time_frame>week 12 and week 16</time_frame>
    <description>Erythema was measured directly after treatment. Mexameter readings ranged from 0 to 100. Higher values describe higher erythema levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>System Usability Scale</measure>
    <time_frame>week 12</time_frame>
    <description>At the end of treatment (visit 7), the usability of the investigational device was evaluated by a questionnaire presented to the patient in German. The usability was evaluated by using the System Usability Scale (SUS) which is an effective tool for assessing the usability of a device. It provides an easy-to-understand score from 0 (negative) to 100 (positive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>It is a simple 10-question validated questionnaire. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. As the change from baseline is calculated negative values in the Outcome Measure Data indicate an improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Use of Topical Co-treatment With Vitamin D of High Intensity (HI) and Low Intensity (LI)</measure>
    <time_frame>patients will be followed for the complete duration of the clinical study for 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Duration of Topical Co-treatment With Vitamin D of High Intensity (HI) and Low Intensity (LI)</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Device Events (Serious and Non-serious)</measure>
    <time_frame>week 0, 1, 2, 4, 8, 12, 16</time_frame>
    <description>Adverse device events: Adverse event related to the use of an investigational medical device wich led to any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons.
Serious adverse device event: Adverse device effect that has resulted in a) led to death, b) led to serious deterioration in the health of the subject, that either resulted in 1) a life-threatening illness or injury, or 2) a permanent impairment of a body structure or a body function, or 3) in-patient or prolonged hospitalization, or 4) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function, c) led to foetal distress, foetal death or a congenital abnormality or birth defect.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hyperpigmentation of &quot;Normal Skin Areas&quot; Surrounding the Target Area Exposed to Blue Light and Control Area Not Exposed to Blue Light- Evaluation by Mexameter</measure>
    <time_frame>week 4, 12, 16</time_frame>
    <description>Arbitrary units measured by mexameter. Mexameter readings ranged from 0 to 100. Higher values correspond to higher pigmentation levels.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events (Serious and Non-serious)</measure>
    <time_frame>week 0, 1, 2, 4, 8, 12, 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Thermal Comfort</measure>
    <time_frame>week 12</time_frame>
    <description>Questionaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Acceptance of Hyperpigmentation</measure>
    <time_frame>week 16</time_frame>
    <description>Questionaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>High Intensity (HI) vs control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity (LI) vs control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PSO-CT02</intervention_name>
    <description>The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.</description>
    <arm_group_label>High Intensity (HI) vs control</arm_group_label>
    <arm_group_label>Low Intensity (LI) vs control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent prior to any study mandated procedure

          2. Good health according to physical examination as determined by the Investigator

          3. Willing and able to comply with study requirements

          4. Skin type I-IV according to Fitzpatrick

          5. Mild plaque-type psoriasis vulgaris with a Psoriasis area severity index (PASI) ≤10
             and Body surface area (BSA)

             ≤10 and Dermatology Life quality index (DLQI) ≤ 10 at screening.

          6. Presence of two comparable psoriatic plaques suitable to be defined as study areas as
             follows:

               1. located on extremities (plaques located on the palms or sole of the feet are not
                  suitable)

               2. Both areas located either on lower or upper extremity

               3. Can be located on the same extremity

               4. Distance between the two study areas &gt; 10cm (border to border)

               5. If lesion is too large to be fully covered, partial treatment possible

          7. Aged ≥ 18 years up to &lt;75 years

          8. Reliable method of contraception for women of childbearing potential (i.e. low failure
             rate less than 1% per year; e.g. oral contraceptives, intra-uterine device [IUD] or
             transdermal contraceptive patch)

          9. Willing to abstain from excessive sun / UV exposure (e.g. sunbathe, solarium) during
             the course of the study.

        Exclusion Criteria:

        General

          1. Inmates of psychiatric wards, prisons, or other state institutions

          2. Investigator or any other team member involved directly or indirectly in the conduct
             of the clinical study

          3. Participation in another clinical trial within the last 30 days

          4. Pregnant or lactating women Medical History

          5. Photodermatosis and/or Photosensitivity

          6. Porphyria and/or hypersensitivity to porphyrins

          7. Patients with current diagnosis of erythrodermic, exfoliative or pustular psoriasis

          8. Congenital or acquired immunodeficiency

          9. Patients with any of the following conditions present on the study areas: Malignoma of
             the skin or severe actinic damage of the skin, atypical naevi or signs of
             hyperpigmentation, viral (e.g. herpes or varicella) lesions of the skin, fungal and
             bacterial skin infections, parasitic infections and atrophic Skin

         10. Patients with genetic deficiencies attached with increased sensitivity to light or
             increased risk to dermatologic cancer (i.e. Xeroderma pigmentosum, Cockayne Syndrome,
             Bloom- Syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Verena von Felbert, PD, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for Dermatology and Allergology, Medical Faculty of the RWTH Aachen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology and Allergology, Medical faculty of the RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <results_first_submitted>August 12, 2015</results_first_submitted>
  <results_first_submitted_qc>October 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2015</results_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patient visits were conducted at the Department of Dermatology and Allergology, RWTH Aachen University Hospital. One hundred and twenty-nine patients were prescreened, 49 patients were screened and 47 enrolled in the study at the time of screening from October 2013 to June 2014.</recruitment_details>
      <pre_assignment_details>Two patients were screening failures, so 47 actually started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Intensity (HI) vs. Control</title>
          <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
        </group>
        <group group_id="P2">
          <title>Low Intensity (LI) vs. Control</title>
          <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Aanalysis Set (FAS)</population>
      <group_list>
        <group group_id="B1">
          <title>High Intensity (HI) vs Control</title>
          <description>PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.
PSO-CT02: The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.</description>
        </group>
        <group group_id="B2">
          <title>Low Intensity (LI) vs Control</title>
          <description>PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.
PSO-CT02: The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.54" spread="13.80"/>
                    <measurement group_id="B2" value="49.09" spread="10.68"/>
                    <measurement group_id="B3" value="47.79" spread="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Visit 2) of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity (HI) Group) as Compared to the Control Area at End of Treatment (Visit 7, Week 12).</title>
        <description>In this study only the “local” PASI (also called local psoriasis severity index – LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
        <time_frame>baseline and week 12</time_frame>
        <population>Full Analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity</description>
          </group>
          <group group_id="O2">
            <title>Control (HI)</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Visit 2) of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity (HI) Group) as Compared to the Control Area at End of Treatment (Visit 7, Week 12).</title>
          <description>In this study only the “local” PASI (also called local psoriasis severity index – LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
          <population>Full Analysis set (FAS)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="1.53"/>
                    <measurement group_id="O2" value="-1.46" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistically analysed were the difference in change from baseline to the end of treatment (week 12) of the target plaque compared to the control plaque.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity) as Compared to the Control Area at End of Treatment During the Attack Period (Week 4, Visit 5)</title>
        <description>In this study only the “local” PASI (also called local psoriasis severity index – LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
        <time_frame>baseline and week 4</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity</description>
          </group>
          <group group_id="O2">
            <title>Control (HI)</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity) as Compared to the Control Area at End of Treatment During the Attack Period (Week 4, Visit 5)</title>
          <description>In this study only the “local” PASI (also called local psoriasis severity index – LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
          <population>Full Analysis Set</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="1.21"/>
                    <measurement group_id="O2" value="-1.33" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistically analysed were the difference in change from baseline to the end of treatment during the attack period (week 4) of the target plaque compared to the control plaque.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 12 of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity) as Compared to the Control Area at End of Follow-up</title>
        <description>In this study only the “local” PASI (also called local psoriasis severity index – LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
        <time_frame>Week 12 and week 16</time_frame>
        <population>Full Analysis Set (FAS); due to one drop out this number is 23 at week 12 and 16</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity</description>
          </group>
          <group group_id="O2">
            <title>Control (HI)</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 12 of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity) as Compared to the Control Area at End of Follow-up</title>
          <description>In this study only the “local” PASI (also called local psoriasis severity index – LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
          <population>Full Analysis Set (FAS); due to one drop out this number is 23 at week 12 and 16</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="1.313"/>
                    <measurement group_id="O2" value="-0.43" spread="1.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistically analysed were the difference in change from end of treatment (week 12, visit 7) to end of follow up (week 16, visit 8) of the target plaque compared to the control plaque.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3075</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline (Visit 2) of the Local Psoriasis Area Severity Index (PASI) of the Target Area (Low Intensity (LI) Group) as Compared to the Control Area by Week.</title>
        <description>In this study only the “local” PASI (also called local psoriasis severity index – LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
        <time_frame>baseline and week 4, 12, 16</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Low Intensity</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity</description>
          </group>
          <group group_id="O2">
            <title>Control (LI)</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Visit 2) of the Local Psoriasis Area Severity Index (PASI) of the Target Area (Low Intensity (LI) Group) as Compared to the Control Area by Week.</title>
          <description>In this study only the “local” PASI (also called local psoriasis severity index – LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked
A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).</description>
          <population>Full Analysis Set (FAS)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="1.557"/>
                    <measurement group_id="O2" value="-0.87" spread="1.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.78" spread="1.347"/>
                    <measurement group_id="O2" value="-2.04" spread="1.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="1.447"/>
                    <measurement group_id="O2" value="-2.50" spread="1.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistically analysed were the difference in change from baseline to week 4 of the target plaque compared to the control plaque.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0140</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistically analysed were the difference in change from baseline to week 12 of the target plaque compared to the control plaque.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistically analysed were the difference in change from baseline to week 16 of the target plaque compared to the control plaque.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1020</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in Change From Baseline of Local Psoriasis Area Severity Index (PASI) Between Target and Control Area of the High Intensity (HI) Group as Compared to the Low Intensity (LI) Group</title>
        <description>In this study only the &quot;local&quot; PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0. = no sign
= slight
= moderate
= marked
= very marked A total severity score was calculated as the sum of the three symptom ratings (range 0-12).</description>
        <time_frame>baseline and week 4, 8, 16</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity</description>
          </group>
          <group group_id="O2">
            <title>Control (HI)</title>
            <description>Contralateral untreated control plaque on the same patient</description>
          </group>
          <group group_id="O3">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity</description>
          </group>
          <group group_id="O4">
            <title>Control (LI)</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Change From Baseline of Local Psoriasis Area Severity Index (PASI) Between Target and Control Area of the High Intensity (HI) Group as Compared to the Low Intensity (LI) Group</title>
          <description>In this study only the &quot;local&quot; PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:
0. = no sign
= slight
= moderate
= marked
= very marked A total severity score was calculated as the sum of the three symptom ratings (range 0-12).</description>
          <population>Full Analysis Set (FAS)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4 n=24 (HI) n=23 (LI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="1.213"/>
                    <measurement group_id="O2" value="-1.33" spread="1.659"/>
                    <measurement group_id="O3" value="-1.83" spread="1.557"/>
                    <measurement group_id="O4" value="-0.87" spread="1.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8 n=24 (HI) n=23 (LI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="1.359"/>
                    <measurement group_id="O2" value="-1.50" spread="1.719"/>
                    <measurement group_id="O3" value="-1.78" spread="1.650"/>
                    <measurement group_id="O4" value="-1.30" spread="1.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16 n=23 (HI) n=22 (LI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" spread="1.619"/>
                    <measurement group_id="O2" value="-1.87" spread="1.842"/>
                    <measurement group_id="O3" value="-3.00" spread="1.447"/>
                    <measurement group_id="O4" value="-2.50" spread="1.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Erythema Evaluated by Mexameter of the Target Area of High Intensity (HI) and Low Intensity (LI) as Compared to the Control Area</title>
        <description>Erythema was measured directly after treatment. Mexameter readings ranged from 0 to 100. Higher values describe higher erythema levels.</description>
        <time_frame>baseline and week 4, 12</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Control (HI)</title>
            <description>Contralateral untreated control plaque on the same patient</description>
          </group>
          <group group_id="O3">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O4">
            <title>Control (LI)</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Erythema Evaluated by Mexameter of the Target Area of High Intensity (HI) and Low Intensity (LI) as Compared to the Control Area</title>
          <description>Erythema was measured directly after treatment. Mexameter readings ranged from 0 to 100. Higher values describe higher erythema levels.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="13.87"/>
                    <measurement group_id="O2" value="1.00" spread="13.45"/>
                    <measurement group_id="O3" value="0.13" spread="11.90"/>
                    <measurement group_id="O4" value="2.87" spread="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="11.02"/>
                    <measurement group_id="O2" value="-0.58" spread="11.82"/>
                    <measurement group_id="O3" value="5.50" spread="16.66"/>
                    <measurement group_id="O4" value="1.05" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 12 (End of Treatment) of Erythema Evaluated by Mexameter of the Target Area of High Intensity (HI) and Low Intensity (LI) as Compared to the Control Area at End of Follow-up</title>
        <description>Erythema was measured directly after treatment. Mexameter readings ranged from 0 to 100. Higher values describe higher erythema levels.</description>
        <time_frame>week 12 and week 16</time_frame>
        <population>Full Analysis Set (FAS); due to one drop out in each group this number is 23 for HI Group and 22 for LI group at week 12 and 16</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Control (HI)</title>
            <description>Contralateral untreated control plaque on the same patient</description>
          </group>
          <group group_id="O3">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O4">
            <title>Control (LI)</title>
            <description>Contralateral untreated control plaque on the same patient</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 12 (End of Treatment) of Erythema Evaluated by Mexameter of the Target Area of High Intensity (HI) and Low Intensity (LI) as Compared to the Control Area at End of Follow-up</title>
          <description>Erythema was measured directly after treatment. Mexameter readings ranged from 0 to 100. Higher values describe higher erythema levels.</description>
          <population>Full Analysis Set (FAS); due to one drop out in each group this number is 23 for HI Group and 22 for LI group at week 12 and 16</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="14.08"/>
                    <measurement group_id="O2" value="2.00" spread="14.97"/>
                    <measurement group_id="O3" value="-1.64" spread="12.07"/>
                    <measurement group_id="O4" value="3.23" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>System Usability Scale</title>
        <description>At the end of treatment (visit 7), the usability of the investigational device was evaluated by a questionnaire presented to the patient in German. The usability was evaluated by using the System Usability Scale (SUS) which is an effective tool for assessing the usability of a device. It provides an easy-to-understand score from 0 (negative) to 100 (positive).</description>
        <time_frame>week 12</time_frame>
        <population>Full Analysis Set (FAS); due to one drop out this number is 23 at week 12 for HI group. Only 17 of 22 patients completed the questionaire in the LI group.</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>System Usability Scale</title>
          <description>At the end of treatment (visit 7), the usability of the investigational device was evaluated by a questionnaire presented to the patient in German. The usability was evaluated by using the System Usability Scale (SUS) which is an effective tool for assessing the usability of a device. It provides an easy-to-understand score from 0 (negative) to 100 (positive).</description>
          <population>Full Analysis Set (FAS); due to one drop out this number is 23 at week 12 for HI group. Only 17 of 22 patients completed the questionaire in the LI group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.37" spread="11.62"/>
                    <measurement group_id="O2" value="88.53" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Dermatology Life Quality Index (DLQI)</title>
        <description>It is a simple 10-question validated questionnaire. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. As the change from baseline is calculated negative values in the Outcome Measure Data indicate an improvement in quality of life.</description>
        <time_frame>baseline and week 12</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Dermatology Life Quality Index (DLQI)</title>
          <description>It is a simple 10-question validated questionnaire. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. As the change from baseline is calculated negative values in the Outcome Measure Data indicate an improvement in quality of life.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="2.98"/>
                    <measurement group_id="O2" value="-0.36" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Use of Topical Co-treatment With Vitamin D of High Intensity (HI) and Low Intensity (LI)</title>
        <time_frame>patients will be followed for the complete duration of the clinical study for 16 weeks</time_frame>
        <population>Full Analysis Set (FAS); Not all patients requested co-use of vitamin D. Only 17 in HI group and 16 in LI group requested co-use of vitamin D</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of Topical Co-treatment With Vitamin D of High Intensity (HI) and Low Intensity (LI)</title>
          <population>Full Analysis Set (FAS); Not all patients requested co-use of vitamin D. Only 17 in HI group and 16 in LI group requested co-use of vitamin D</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.35" spread="17.68"/>
                    <measurement group_id="O2" value="48.25" spread="26.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Duration of Topical Co-treatment With Vitamin D of High Intensity (HI) and Low Intensity (LI)</title>
        <time_frame>week 16</time_frame>
        <population>Full Analysis Set (FAS); Not all patients requested co-use of vitamin D. Only 17 in HI group and 16 in LI group requested co-use of vitamin D</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Duration of Topical Co-treatment With Vitamin D of High Intensity (HI) and Low Intensity (LI)</title>
          <population>Full Analysis Set (FAS); Not all patients requested co-use of vitamin D. Only 17 in HI group and 16 in LI group requested co-use of vitamin D</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.65" spread="23.82"/>
                    <measurement group_id="O2" value="53.44" spread="33.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hyperpigmentation of &quot;Normal Skin Areas&quot; Surrounding the Target Area Exposed to Blue Light and Control Area Not Exposed to Blue Light- Evaluation by Mexameter</title>
        <description>Arbitrary units measured by mexameter. Mexameter readings ranged from 0 to 100. Higher values correspond to higher pigmentation levels.</description>
        <time_frame>week 4, 12, 16</time_frame>
        <population>Safety Set (SAF)</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity</description>
          </group>
          <group group_id="O2">
            <title>Control (HI)</title>
            <description>Contralateral untreated control plaque on the same patient</description>
          </group>
          <group group_id="O3">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity</description>
          </group>
          <group group_id="O4">
            <title>Control (LI)</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperpigmentation of &quot;Normal Skin Areas&quot; Surrounding the Target Area Exposed to Blue Light and Control Area Not Exposed to Blue Light- Evaluation by Mexameter</title>
          <description>Arbitrary units measured by mexameter. Mexameter readings ranged from 0 to 100. Higher values correspond to higher pigmentation levels.</description>
          <population>Safety Set (SAF)</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.88" spread="6.02"/>
                    <measurement group_id="O2" value="26.58" spread="6.80"/>
                    <measurement group_id="O3" value="25.09" spread="7.86"/>
                    <measurement group_id="O4" value="23.48" spread="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.71" spread="6.75"/>
                    <measurement group_id="O2" value="25.17" spread="4.65"/>
                    <measurement group_id="O3" value="24.50" spread="6.81"/>
                    <measurement group_id="O4" value="24.18" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.17" spread="8.61"/>
                    <measurement group_id="O2" value="26.39" spread="5.99"/>
                    <measurement group_id="O3" value="25.05" spread="6.45"/>
                    <measurement group_id="O4" value="22.95" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Events (Serious and Non-serious)</title>
        <time_frame>week 0, 1, 2, 4, 8, 12, 16</time_frame>
        <population>Safety Set (SAF)</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (Serious and Non-serious)</title>
          <population>Safety Set (SAF)</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Device Events (Serious and Non-serious)</title>
        <description>Adverse device events: Adverse event related to the use of an investigational medical device wich led to any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons.
Serious adverse device event: Adverse device effect that has resulted in a) led to death, b) led to serious deterioration in the health of the subject, that either resulted in 1) a life-threatening illness or injury, or 2) a permanent impairment of a body structure or a body function, or 3) in-patient or prolonged hospitalization, or 4) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function, c) led to foetal distress, foetal death or a congenital abnormality or birth defect.</description>
        <time_frame>week 0, 1, 2, 4, 8, 12, 16</time_frame>
        <population>Safety Set (SAF)</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Device Events (Serious and Non-serious)</title>
          <description>Adverse device events: Adverse event related to the use of an investigational medical device wich led to any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons.
Serious adverse device event: Adverse device effect that has resulted in a) led to death, b) led to serious deterioration in the health of the subject, that either resulted in 1) a life-threatening illness or injury, or 2) a permanent impairment of a body structure or a body function, or 3) in-patient or prolonged hospitalization, or 4) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function, c) led to foetal distress, foetal death or a congenital abnormality or birth defect.</description>
          <population>Safety Set (SAF)</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>non serious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Thermal Comfort</title>
        <description>Questionaire</description>
        <time_frame>week 12</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Thermal Comfort</title>
          <description>Questionaire</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very uncomfortable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncomfortable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little uncomfortable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17"/>
                    <measurement group_id="O2" value="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Just right</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00"/>
                    <measurement group_id="O2" value="30.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little comfortable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17"/>
                    <measurement group_id="O2" value="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comfortable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.33"/>
                    <measurement group_id="O2" value="47.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very comfortable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient Acceptance of Hyperpigmentation</title>
        <description>Questionaire</description>
        <time_frame>week 16</time_frame>
        <population>Safety set (SAF)</population>
        <group_list>
          <group group_id="O1">
            <title>High Intensity (HI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
          <group group_id="O2">
            <title>Low Intensity (LI)</title>
            <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Acceptance of Hyperpigmentation</title>
          <description>Questionaire</description>
          <population>Safety set (SAF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acceptable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="47.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Hyperpigmentation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.67"/>
                    <measurement group_id="O2" value="47.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33"/>
                    <measurement group_id="O2" value="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Intensity (HI)</title>
          <description>PSO-CT02 device: Light wavelength 453nm, high intensity versus contralateral untreated control plaque on the same patient.</description>
        </group>
        <group group_id="E2">
          <title>Low Intensity (LI)</title>
          <description>PSO-CT02 device: Light wavelength 453nm, low intensity versus contralateral untreated control plaque on the same patient.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Matthias Born</name_or_title>
      <organization>Philips GmbH Innovative Technologies Aachen</organization>
      <phone>+491735321764</phone>
      <email>matthias.born@philips.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

